Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep;1(2):87-93.
doi: 10.1016/S0973-6883(11)60127-8. Epub 2011 Nov 9.

Pathophysiology of portal hypertension and its clinical links

Yeon Seok Seo  1 , Vijay H Shah  2
Affiliations
Review

Pathophysiology of portal hypertension and its clinical links

Yeon Seok Seo et al. J Clin Exp Hepatol. 2011 Sep.

Abstract

Portal hypertension is a major cause of morbidity and mortality in patients with liver cirrhosis. Intrahepatic vascular resistance due to architectural distortion and intrahepatic vasoconstriction, increased portal blood flow due to splanchnic vasodilatation, and development of collateral circulation have been considered as major factors for the development of portal hypertension. Recently, sinusoidal remodeling and angiogenesis have been focused as potential etiologic factors and various researchers have tried to improve portal hypertension by modulating these new targets. This article reviews potential new treatments in the context of portal hypertension pathophysiology concepts.

Keywords: AT, angiotensin; ET-1, endothelin-1; HSC, hepatic stellate cell; HVPG, hepatic venous pressure gradient; NO, nitric oxide; PDGF, platelet-derived growth factor; PIGF, placenta! growth factor; RAS, renin-angiotensin system; RCT, randomized controlled trial; VEGF, vascular endothelial growth factor; angiogenesis; eNOS, endothelial nitric oxide synthase; pathophysiology; portal hypertension; sinusoids; treatment.

PubMed Disclaimer

References

    1. Reuben A, Groszmann RJ. Portal hypertension: a history. In: Sanyal AJ, Shah VH, editors. Portal Hypertension. Humana Press; Totowa NJ: 2005. pp. 3–11.
    1. Shah VH, Kamath PS. Portal hypertension and gastrointestinal bleeding. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Saunders; Philadelphia, PA: 2010. pp. 1489–1516.
    1. Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Baillieres Clin Gastroenterol. 1997;11:203–219. - PubMed
    1. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325–337. - PubMed
    1. Morales-Ruiz M. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003;125:522–531. - PubMed